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Summary
Background National guidelines for treating type 2
diabetes in the Balkans generally follow European
guidelines. The current study was undertaken to
estimate the rate of glycated hemoglobin (HbA1c)
measurements and level of HbA1c control in diabetic
patients treated in regular clinical practice settings in
the Balkans and to evaluate if providing HbA1c mea-
surements improves adherence to treatment guide-
lines.
Methods This cross-sectional study enrolled type 2
diabetic patients treated by 79 primary care physi-
cians and 102 specialists. The participants were
provided with HbA1c measuring devices to measure
HbA1c during regular office visits and a physician sur-
vey evaluated HbA1c the results feedback. Relevant
clinical, demographic, drug treatment and special-
ist referral data were extracted from patient charts.
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Descriptive statistics and stepwise multivariate re-
gression analysis were used.
Results Among 1853 patients included (average age
63.5 ± 10.7 years, 51% male) the average diabetes
duration was 8.9 ± 7.1 years, 40% of patients had
HbA1c measured every 6 months and 34% every
12 months (or less frequently). The rate of 6-month
measurement was higher among specialists (43%)
vs. primary care physicians (32%, p < 0.01). The
average HbA1c was 7.3 ± 1.5 and 35% of patients
achieved the target HbA1c level of < 6.5%. Metformin
monotherapy was prescribed to 28% of patients and
metformin + sulphonylurea to 23%, 55% of patients
on metformin monotherapy and 32% of patients on
dual therapy metformin + sulphonylurea achieved the
target HbA1c < 6.5%. Treatment remained unchanged
in 91% and was stepped up in only 7.2% of patients.
Physicians were not surprised (in 79% of patients)
or were pleasantly surprised (in 11%) by the HbA1c
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Table 1 Studyflowchart
Approximate dura-
tion in months
Planning and obtaining approval from authorities
(ethical and regulatory agency approval)
2
Investigators meeting, training for doctors involved in
study procedures, including the use of measurement
devices
1
Recruiting patients, obtaining informed consent and
collecting data
1
Collecting of case report forms (CRF) 1
Data analysis 1
results at the time of visit. Average diabetes duration
and patient use of home glucometers were associated
with the level of disease control.
Conclusions The rates of HbA1c measurements re-
main low in the Balkans, although higher among spe-
cialists. Over 60% of patients, mostly treated with
traditional oral antidiabetics did not achieve disease
control. Providing convenient HbA1c measurement
devices was not associated with a marked change in
diabetes management. Future research is needed to
evaluate the impact of these treatment patterns on
long-term outcomes and costs to society.
Keywords Type 2 diabetes · Clinical practice · HbA1c
measurement rate · Glycemic control · Diabetes ther-
apy
Introduction
Diabetes mellitus (DM) is a chronic disease that
requires continuous medical care and patient self-
management, education and support in order to pre-
vent acute complications and reduce the risk of long-
term complications. It is considered one of the great-
est health challenges of the twenty-first century. In
2013 DM caused 5.1 million deaths [1] and a per-
son dies from diabetes every 6 s [1]. According to
the International Diabetes Federation (IDF), 8.3%
of adults have diabetes, and the number of people
living with diabetes is expected to rise from 382 mil-
lion in 2013 to 592 million in less than 25 years [1].
Type 2 DM accounts for 90% of all diabetes cases
[2]. The 2006 World Health Organization (WHO)
diagnostic criteria for diabetes are fasting plasma glu-
cose ≥7.0mmol/l (126mg/dl) or 2-h plasma glucose
≥11.1mmol/l (200mg/dl) [3]. In 2009, an interna-
tional expert committee including representatives of
the American Diabetes Association (ADA), the IDF
and the European Association for the Study of Di-
abetes (EASD) recommended the use of the HbA1c
test to diagnose diabetes, with a threshold of ≥6.5%
(48mmol/mol) and the ADA adopted this criterion
in 2010. Furthermore, the two most influential large-
scale clinical trials of diabetes therapeutic regimens,
the Diabetes Control and Complications Trial (DCCT)
and the United Kingdom Prospective Diabetes Study
(UKPDS), have shown that improving HbA1c levels
slows the development and progression of eye, kidney,
and nerve complications in both type 1 and type 2 DM
[4–6]. There are two primary techniques available to
assess the effectiveness of the glycemic control man-
agement plan: blood glucose and HbA1c monitoring
[7]. The most abundant minor hemoglobin compo-
nent is HbA1c and it is formed by the chemical con-
densation of hemoglobin and glucose [6, 8]. Glycated
hemoglobin is measured primarily to identify aver-
age plasma glucose concentrations over prolonged
periods of time and HbA1c has a strong predictive
value for diabetes complications [9–12]. The target
HbA1c level is <6.5% (48mmol/mol) and this con-
centration is recommended as a diagnostic indicator
of disease control and the effectiveness of therapy.
The test should be repeated every 3 months until the
target value is reached, and every 6 months thereafter
[13–17]. If dietary treatment for DM is not effective,
then pharmacological treatment is usually initiated.
Unless contraindicated, metformin is recommended
as a first line therapy in addition to diet and exercise.
National guidelines for treating DM in the Balkans
generally follow European guidelines; however, the
rate of routine HbA1c measurements in type 2 DM
patient care among practitioners in the Balkans is un-
certain. The current study was undertaken to estimate
the rate of HbA1c measurement and the level of dis-
ease control in patients with type 2 DM in the Balkans,
and to evaluate if providing a cost free and simple
way to measure HbA1c levels leads to the more ag-
gressive treatment of patients who have poor disease
control. The primary objective of this study was to
determine the rate of HbA1c testing in patients with
type 2 DM among general practitioners (GPs) and di-
abetes specialists, and to estimate adherence to treat-
ment guidelines. The secondary objective was to es-
tablish whether HbA1c testing improves adherence to
treatment guidelines.
Patients, materials and methods
The study was performed as a multicenter study in the
Balkan countries, represented by Croatia, Slovenia,
Serbia, Romania, and Bulgaria. This study was per-
formed as an observational, non-interventional, and
cross-sectional study. It was performed over 3-month
periods, in 2013 and the beginning of 2014 (Table 1,
available online).
HbA1c measurement
Physicians were provided with HbA1c measuring de-
vices (Siemens, Erlangen, Germany) for the purpose
of the study [18].
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Diagnostic criteria
Diabetes was defined according to the 2006 WHO di-
agnostic criteria as fasting plasma glucose ≥7.0mmol/l
(126mg/dl) or 2-h plasma glucose ≥11.1mmol/l
(200mg/dl) [3].
Physicians
The participating physicians represented different re-
gions of the Balkan countries. The target was to enrol
equal numbers of general practitioners and special-
ists in each country, except in Romania, where only
specialists were enrolled due to the fact that patients
with type 2 diabetes are treated only by internists/
diabetologists. A total of 181 physicians participated
in this study of whom 79 were GP/general medi-
cal specialists and 102 were internists/diabetologists.
All participating physicians attended several training
meetings and were certified before recruitment. The
physicians were divided into three groups according
to HbA1c measurement frequency. At the end of the
study, physicians were asked to provide feedback as
to whether the HbA1c level results of their patients
were as expected, better than expected, or worse than
expected.
Patients
Eligible patients with type 2 DMwere adults (≥18 years
of age) treated with oral antihyperglycemic agents or
insulin at least 6 months before enrollment. A total
of 1853 patients were enrolled, 479 patients treated
by GP and 1331 regularly seen by diabetes specialists.
The patients were recruited during regular office visits
after signing an informed consent form. The popula-
tion living in the study area was genetically a rela-
tively uniformly Caucasian population, and no differ-
ent ethnic groups were expected to be living there.
The total population of the Balkans is 59 million of
whom 34 million are adults between 27 and 69 years
of age. Bearing in mind that the average prevalence
of diabetes in the region was 7.6% in 2013 accord-
ing to the IDF, the rough estimate is that there were
approximately 3 million adults with diabetes in the re-
gion at the time the study was conducted [1]. Patient
history data were taken along with HbA1c measure-
ments. Fingerprick testing of HbA1c was performed
on site [18]. Diabetes therapy on the visit date and any
change in therapy on the same date, possible referral
to a specialist, prior medication history, and records
of prior medication taken by the subject within the
past 6 months before the study were all noted.
General informed consent
General informed consent was documented with
a consent form signed and dated by both the subject
or the subject’s legal representative and the person
conducting the consent discussion. A copy of the
signed and dated consent form was given to the sub-
ject before their participation in the study. Informed
consent adheres to institutional review board/ethics
review committee (IRB/ERC) requirements, applica-
ble laws and regulations, and Sponsor requirements.
Statistical analysis
All statistical analysis was performed using Statistical
Package for the Social Sciences (SPSS) version 17.0
for Windows (SPSS, Chicago, IL). The statistical meth-
ods used for the requirements of the study were tests
of the statistical significance of differences between
proportions and Student’s t-test. According to the
power analysis, each subsample should have at least
21 physicians and 80 patients to have sufficient power
(0.9) for the desired effect size and significance level
(0.05). The study was designed to have 90% power
to detect a difference of 5%. A p-value of 0.05 was
considered statistically significant. Although the pa-
tients were recruited using a two-step procedure, the
recruiting physician was not used as a random fac-
tor in the analysis The preliminary variance compo-
nents analysis showed that the recruiting site does
not have a significant impact on primary outcome
(HbA1c level), showing no significance for either re-
cruiting physician or the interaction with country or
GP/specialist. This is probably due to both the rela-
tively low number of patients per doctor [10] and the
fact that the patients are not necessarily treated by the
recruiting doctor.
Results
Patient baseline characteristics
All patients were adults between 20 and 92 years
of age (average age 63.5 ± 10.7 years). They had
been diagnosed with type 2 DM for 1–61 years (av-
erage 8.9 ± 7.1 years) and 51% were male. Of the
patients 35% had achieved the target HbA1c value
of <6.5% (48mmol/mol), while 33% had HbA1c lev-
els >7.5% (58mmol/mol). Measurement of HbA1c
was found to be quite infrequent, with only 40% of
patients having their hemoglobin measured at least
every 6 months and as many as 34% less than every
12 months or never (Fig. 1).
Glycemic control
The results of the present study showed that the level
of glycemic control in the region was poor, with an av-
erage HbA1c level of 7.3% ± 1.5 (56mmol/mol). The
difference between the proportion of well-controlled
patients was not statistically significant between doc-
tors who do and do not have access to HbA1c mea-
surement, nor were they statistically significant be-
tween GPs and specialists (p = 0.87 and 0.099, respec-
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Fig. 1 Relationshipbe-
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tively). The difference between the proportion of well-
controlled patients of doctors who measured HbA1c
often and of those who do not was not statistically
significant either (p > 0.05).
HbA1c measurement
It is important to note that the proportion of pa-
tients with adequate glycemic control ranged from
23–50% (Fig. 2). It was significantly lower in Croatia,
as compared with Serbia, Slovenia, and Bulgaria, and
was significantly higher in Bulgaria than any other
Balkan country except for Serbia, where the differ-
ence is not statistically significant. The proportion
of patients with adequate glycemic control was sig-
nificantly lower in patients of specialists across the
entire sample (p = 0.016). These differences are not
significant for Bulgaria, Croatia, or Serbia (p = 0.4, 0.6
and 0.2, respectively) but are significant for Slovenia
(p = 0.001).
Frequency of measurement
The frequency of measurement was also found to be
higher in patients regularly monitored by specialists
(43% vs. 32% of patients monitored at least every
6 months, p < 0.01) (Figs. 1, 3 and 4).
Diabetes therapy
The most frequent therapy was shown to be met-
formin monotherapy (28% of patients), followed by
a combination of metformin and sulphonylurea (23%)
regardless of a low level of disease control in those
patients (Fig. 5). Furthermore, adequate disease con-
trol was achieved in 55% of patients undergoing met-
formin monotherapy and in 32% undergoing com-
bined therapy.
Patients treated with metformin had established
better disease control; however, 40% of them still
showed no improvement. Insulin was also quite
prevalent, and was the only drug prescribed almost
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Fig. 3 Relationship
betweenavailability of
point-of-careHbA1c test-
ingdevice andadequate
glycemic control achieve-
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Fig. 4 Relationshipbe-
tweenHbA1ctesting interval
andadequateglycemiccon-
trol achievement (HbA1c<
6.5%)
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exclusively by specialists; however, patients on insulin
were very poorly controlled. The difference between
metformin and insulin prescription was statistically
significant between GPs and specialists (p = 0.007 and
p < 0.001, respectively). The use of the drug showed
a similar general pattern across the countries in both
subsamples.
Changes in therapy and interventions
Measurement of HbA1c in physician’s offices resulted
in only a small percentage of therapy changes or in-
terventions in patients with an HbA1c level ≥6.5%
(48mmol/mol); therapy was unchanged in 91% of
cases, stepped up in only 7.2% of cases, adding
sulphonylurea to metformin, prescribing a dipeptidyl
peptidase-4 (DPP-4) inhibitor, introducing insulin
or other drugs (Figs. 6 and 7). Another interesting
fact noted was that therapy was stepped down for
2% of patients by switching from combined met-
formin and sulphonylurea therapy to monotherapy
(Fig. 6). Finally, doctors were mostly not surprised
(79%) or were pleasantly surprised (11%) by the pa-
tients HbA1c results and 53% of doctors stated that
they would monitor HbA1c more frequently in the
future.
A stepwise multivariate regression across patient
characteristics (age, time since diagnosis, treated by
GP or specialist) and manner of disease monitoring
(measuring blood glucose using glucometer at home
or measuring HbA1c) and frequency of measurement
(number of blood glucose measurements or time
since last HbA1c measurement) yielded a statistically
significant model with the major predictor variable
impact of type-2 DM time since diagnosis (signifi-
cance <0.001, predictor importance 0.608) and the
use of blood glucose as a measurement tool (signifi-
cance <0.001, predictor importance 0.240). The usage
and the frequency of HbA1c measurement was not
shown to significantly influence DM control in the
region.
Discussion
People with Type 2 DM can remain undiagnosed for
many years, unaware of the long-term damage caused
by the disease. The struggle for tight glycemic control
results in large blood glucose fluctuations over time.
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Fig. 5 Initial diabetes ther-
apy (Metmetformin,DPP-
4idipeptidyl peptidase-4 in-
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tidyl peptidase-4 inhibitor +
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Fig. 6 Therapeutic in-
terventionapproach in
patientswith inadequate
glucosecontrol (SU sulpho-
nylurea,DPP-4idipeptidyl
peptidase-4 inhibitor)
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These fluctuations are the measurable result of the ac-
tion of a complex dynamic system that is influenced
by many internal and external factors, including the
timing and amount of insulin and other drug thera-
pies, diet, physical activity. [19].
Routine HbA1c measurement
The level of HbA1c provides a reliable measure of
chronic glycemic control without the need for a fast-
ing or timed sample. Routine measurement of HbA1c
has remained the standard biomarker and the gold
standard for monitoring glycemic control in patients
with diabetes [8, 19]. Evidence shows that having an
HbA1c result at the time of a doctor’s visit is benefi-
cial [11]. According to previous studies HbA1c is also
a practical and convenient tool for screening undiag-
nosed diabetes in a routine health check-up [7, 20–22,
27].
The rate of routine measurements of HbA1c in
Type 2 DM patient care in the Balkans is uncer-
tain. The results of a study performed in Croatia in
2011 implied poor glycemic control [16]. The level
of glycemic control in patients is unknown both in
Croatia and in other Balkan countries. According to
the results of the study, measurement of HbA1c is
generally quite low, especially in GP patients, and is
lower than 50% in all countries. Specialists measure
HbA1c more often in Croatia and Serbia, while in
Slovenia and Bulgaria they measure it just as rarely
as GPs. In general 50% of GP patients and 41% of
specialist patients did not have HbA1c measurements
taken in over 1 year. Significantly, if the patient is seen
more frequently by a specialist, it is more likely that
a current HbA1c measurement is available. A higher
frequency of measurement by specialists is likely due
to better access to measurement in hospitals and
specialists’ higher level of education.; however, not
even specialists seem to measure HbA1c for all pa-
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Fig. 7 Relationshipbe-
tween therapeutic interven-
tionapproachbystepping
upor steppingdown ther-
apyandHbA1cmeasure at
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tients. The significantly lower proportion of patients
at specialists with adequate glycemic control can be
explained by the referral of more difficult patients
from GPs to specialists for therapy modification and
more strictly controlled treatment. Existing data show
that real-time HbA1c estimation could increase pa-
tient motivation to improve diabetes control [19].
Cut-off value
Although the results of HbA1c measurement in this
study were poor (only 35% of patients had HbA1c <
6.5%), less strict thresholds would only moderately in-
crease the proportion of well-controlled patients but
still leave a considerable proportion poorly controlled,
regardless of the criteria used. It is incumbent on
the clinician to know when HbA1c results should be
questioned, such as when the value is discordant from
the patient’s self-monitoring blood glucose values, or
when there has been an acute change in glycemia,
such as recent treatment with glucocorticoids [8].
Therapy
Patients on metformin were better controlled but
more than 40% were not. Noticeably, patients on
insulin were very poorly controlled, implying the late
introduction of insulin; however, it was noticed that
therapy was stepped up only for a small number of
patients (5–7%).
Self-management
Self-management is achievable through adherence to
professional advice regarding diet, exercise, andmedi-
cation. The effectiveness of structured self-monitored
blood glucose testing has an empowerment effect on
the patient and results in better metabolic control in
people with type 2 DM [23]. The more active par-
ticipation of patients in self-care management pro-
duces better metabolic outcomes and better compli-
ance with treatment protocols [23]. A study performed
in the Balkans included only adult patients. A study on
elderly type 2 DM patients showed that HbA1c is a rel-
evant tool for assessing patient glycemic control and
adherence [24]. Complimentarily, HbA1c measured
at gestational DM (GDM) diagnosis may be a useful
tool for identifying GDM patients at highest risk of
developing postpartum abnormal glucose [25]. Con-
sidering the fact that weight-related problems are on
the rise in many populations worldwide, diabetes ex-
perts are still leading the battle against DM. The pro-
gression of diabetes can also be delayed by intensive
intervention [26].
Study strengths and limitations
The strengths of the study are the comprehensive ap-
proach to its design as an observational, noninter-
ventional, and cross-sectional study, the highly-struc-
tured protocol, and the set of statistical analyses to
determine the effects of protocol completion. There
were no major limitations to this study. The lack of
a control is a minor limitation of this observational
study; however, the design is appropriate for the in-
tended purpose of the study.
Conclusion
Type 2 DM is a noteworthy preventable disease and
an increasing public health problem [26]. Effective
management requires partnership between diabetes
patients and health professionals. The appropriate
use of structured self-monitoring of blood glucose sig-
nificantly improves glycemic control and facilitates
adherence to recommendations about nutrition and
physical activity as well as more timely and aggressive
treatment changes without decreasing general wellbe-
ing [28].
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The main finding of this study is that the provision
of an easy to use and cost-free HbA1c measurement
device does not positively influence treatment pat-
terns of patients with type 2 DM in the Balkans.
In this age of modern technology, online monitor-
ing, and available testing it is unacceptable that less
than 50% of diabetes patients are well-controlled.
Emerging technologies have created continuous glu-
cose monitoring systems that allow frequent, real
time glucose measurements, which may possibly be
superior to oral glucose tolerance test (OGTT) and
HbA1c measurement [29]. The move towards HbA1c-
based diagnosis has obviously generated controversy.
Unfortunately, diabetes is still not under control in
the Balkans. More studies are necessary to explore
the reasons for this phenomenon. The usage and
frequency of HbA1c measurement was not shown
to significantly influence DM control in the region.
Nevertheless, the results that this study has produced
show that HbA1c measurement should be performed
strictly according to the guidelines.
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